Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × abiraterone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 69 Neoplasm Metastasis 9 Prostatic Neoplasms, Castration-Resistant 5 Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Metastatic Castration-Resistant Prostate Cancer 3 Urogenital Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Primary Myelofibrosis 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Myeloproliferative Disorders 2 Myelodysplastic Syndromes 2 Multiple Myeloma 2 Metastatic Castration-resistant Prostate Cancer (mCRPC) 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Colorectal Neoplasms 2 Bulbo-Spinal Atrophy, X-Linked 2 Breast Neoplasms 2 Bites and Stings 2 Uterine Cervical Neoplasms 1 Thrombocytosis 1 Salivary Gland Neoplasms 1 Prostatic Diseases 1 Prostate Cancer Metastatic Disease 1 Prostate Adenocarcinoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1

Interventions

Oxaliplatin 42 Gemcitabine 41 Fluorouracil 37 pembrolizumab 29 Capecitabine 29 Leucovorin 26 Docetaxel 25 Cisplatin 24 Paclitaxel 21 Carboplatin 18 Bevacizumab 17 Irinotecan 16 130-nm albumin-bound paclitaxel 16 Radiotherapy 15 Pemetrexed 15 Nivolumab 13 Albumin-Bound Paclitaxel 13 Cyclophosphamide 10 Ramucirumab 9 zolbetuximab 7 Trastuzumab 7 Radiosurgery 7 Drug Therapy 7 trastuzumab deruxtecan 6 cemiplimab 6 Taxes 6 Erlotinib Hydrochloride 6 Blood Specimen Collection 6 durvalumab 5 Sorafenib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06592924 2026-01-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡